Alisha Vanessa Weiss-Haug, Reka Agnes Haraszti, Stefan Hug, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke
{"title":"异体造血细胞移植作为细胞免疫疗法的范例。","authors":"Alisha Vanessa Weiss-Haug, Reka Agnes Haraszti, Stefan Hug, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke","doi":"10.1159/000543928","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allogeneic hematopoietic cell transplantation (alloHCT) is an established curative treatment for hematologic malignancies and other severe blood disorders. However, alloHCT is also known for its significant side-effects.</p><p><strong>Summary: </strong>Here we review recent advances in targeted molecular therapy, immunotherapy, infectiology and diagnostics that have enhanced the tolerability and the efficacy of alloHCT, expanding its use to less fit and elderly patients. We analyze developments in conditioning regimens, donor selection and the management of graft versus host disease (GVHD) and infections and discuss post-transplantation strategies to prevent relapse.</p><p><strong>Key message: </strong>In a fresh perspective alloHCT can serve as a platform to enhance the potential of emerging targeted and immune therapies.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-21"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Allogeneic Hemopoietic Cell Transplantation as a Paradigm for Cellular Immunotherapy.\",\"authors\":\"Alisha Vanessa Weiss-Haug, Reka Agnes Haraszti, Stefan Hug, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke\",\"doi\":\"10.1159/000543928\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Allogeneic hematopoietic cell transplantation (alloHCT) is an established curative treatment for hematologic malignancies and other severe blood disorders. However, alloHCT is also known for its significant side-effects.</p><p><strong>Summary: </strong>Here we review recent advances in targeted molecular therapy, immunotherapy, infectiology and diagnostics that have enhanced the tolerability and the efficacy of alloHCT, expanding its use to less fit and elderly patients. We analyze developments in conditioning regimens, donor selection and the management of graft versus host disease (GVHD) and infections and discuss post-transplantation strategies to prevent relapse.</p><p><strong>Key message: </strong>In a fresh perspective alloHCT can serve as a platform to enhance the potential of emerging targeted and immune therapies.</p>\",\"PeriodicalId\":19543,\"journal\":{\"name\":\"Oncology Research and Treatment\",\"volume\":\" \",\"pages\":\"1-21\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000543928\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543928","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Allogeneic Hemopoietic Cell Transplantation as a Paradigm for Cellular Immunotherapy.
Background: Allogeneic hematopoietic cell transplantation (alloHCT) is an established curative treatment for hematologic malignancies and other severe blood disorders. However, alloHCT is also known for its significant side-effects.
Summary: Here we review recent advances in targeted molecular therapy, immunotherapy, infectiology and diagnostics that have enhanced the tolerability and the efficacy of alloHCT, expanding its use to less fit and elderly patients. We analyze developments in conditioning regimens, donor selection and the management of graft versus host disease (GVHD) and infections and discuss post-transplantation strategies to prevent relapse.
Key message: In a fresh perspective alloHCT can serve as a platform to enhance the potential of emerging targeted and immune therapies.
期刊介绍：
With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
